Gohibic™ (vilobelimab) – New emergency use authorization
April 4, 2023 - The FDA announced the emergency use authorization (EUA) of InflaRx’s Gohibic (vilobelimab), for the treatment of coronavirus disease 19 (COVID-19) in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation (IMV), or extracorporeal membrane oxygenation (ECMO).
Top